A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Anumigilimab in Patients with Hidradenitis Suppurativa Who Have Had an Inadequate Response to Anti-TNF Therapy
D
David Rosmarin
Primary Investigator
Recruiting
18-100 years
All
Phase
2
5 participants needed
1 Location
Brief description of study
Hidradenitis suppurativa (HS) is a painful skin condition with recurring lumps, abscesses, and tunnels that drain unpleasant fluids, significantly affecting quality of life.
What is the purpose of this study?
The primary objective of the study is to evaluate the efficacy of anumigilimab administered in Treatment Period A to subjects with moderate to severe Hidradenitis suppurativa who have had an
inadequate response to anti-TNF therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Hidradenitis Suppurativa
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
- Aged ≥ 18 years at the time of consent.
- Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
- Not pregnant or breast feeding
- Willing and able to comply with the study Protocol and procedures, including photography.
- Does not have any active infections, cancer, or heart disease
Updated on
01 Aug 2024.
Study ID: DERM-CSL-324-2001
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
